ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment for Unresectable RAS and BRAF Wild-Type mCRC: Results of the Phase III Randomized TRIPLETE Study by GONO
By
ASCO 2022 Conference Coverage
FEATURING
Chiara Cremolini
By
ASCO 2022 Conference Coverage
FEATURING
Chiara Cremolini
191 views
June 10, 2022
Comments 0
Login to view comments.
Click here to Login
GI